| The art of modeling PL Bonate Pharmacokinetic-pharmacodynamic modeling and simulation, 1-56, 2006 | 929 | 2006 |
| Analysis of pretest-posttest designs PL Bonate Chapman and Hall/CRC, 2000 | 589 | 2000 |
| Discovery and development of clofarabine: a nucleoside analogue for treating cancer PL Bonate, L Arthaud, WR Cantrell Jr, K Stephenson, JA Secrist III, ... Nature reviews Drug discovery 5 (10), 855-863, 2006 | 319 | 2006 |
| Results of a phase 1-2 study of clofarabine in combination with cytarabine (ara-C) in relapsed and refractory acute leukemias S Faderl, V Gandhi, S O'Brien, P Bonate, J Cortes, E Estey, M Beran, ... Blood 105 (3), 940-947, 2005 | 256 | 2005 |
| A brief introduction to Monte Carlo simulation PL Bonate Clinical pharmacokinetics 40, 15-22, 2001 | 235 | 2001 |
| Phase II study evaluating 2 dosing schedules of oral foretinib (GSK1363089), cMET/VEGFR2 inhibitor, in patients with metastatic gastric cancer MA Shah, ZA Wainberg, DVT Catenacci, HS Hochster, J Ford, P Kunz, ... PloS one 8 (3), e54014, 2013 | 228 | 2013 |
| A phase 2 study of eliglustat tartrate (Genz-112638), an oral substrate reduction therapy for Gaucher disease type 1 E Lukina, N Watman, EA Arreguin, M Banikazemi, M Dragosky, ... Blood, The Journal of the American Society of Hematology 116 (6), 893-899, 2010 | 180 | 2010 |
| Scientific white paper on concentration-QTc modeling C Garnett, PL Bonate, Q Dang, G Ferber, D Huang, J Liu, D Mehrotra, ... Journal of Pharmacokinetics and Pharmacodynamics 45, 383-397, 2018 | 167 | 2018 |
| The effect of collinearity on parameter estimates in nonlinear mixed effect models PL Bonate Pharmaceutical research 16, 709-717, 1999 | 149 | 1999 |
| Population pharmacokinetics–pharmacodynamics of alemtuzumab (Campath®) in patients with chronic lymphocytic leukaemia and its link to treatment response DR Mould, A Baumann, J Kuhlmann, MJ Keating, S Weitman, P Hillmen, ... British journal of clinical pharmacology 64 (3), 278-291, 2007 | 131 | 2007 |
| Clinical trial simulation in drug development PL Bonate Pharmaceutical research 17, 252-256, 2000 | 124 | 2000 |
| Drug interactions at the renal level: implications for drug development PL Bonate, K Reith, S Weir Clinical pharmacokinetics 34 (5), 375-404, 1998 | 120 | 1998 |
| Pharmacokinetics and pharmacodynamics of plasma clofarabine and cellular clofarabine triphosphate in patients with acute leukemias V Gandhi, H Kantarjian, S Faderl, P Bonate, M Du, M Ayres, MB Rios, ... Clinical cancer research 9 (17), 6335-6342, 2003 | 111 | 2003 |
| Population pharmacokinetics of isavuconazole from phase 1 and phase 3 (SECURE) trials in adults and target attainment in patients with invasive infections due to Aspergillus … A Desai, L Kovanda, D Kowalski, Q Lu, R Townsend, PL Bonate Antimicrobial Agents and Chemotherapy 60 (9), 5483-5491, 2016 | 108 | 2016 |
| Pathophysiology and pharmacokinetics following burn injury PL Bonate Clinical pharmacokinetics 18, 118-130, 1990 | 96 | 1990 |
| Exposure-response relationships for isavuconazole in patients with invasive aspergillosis and other filamentous fungi AV Desai, LL Kovanda, WW Hope, D Andes, JW Mouton, DL Kowalski, ... Antimicrobial Agents and Chemotherapy 61 (12), 10.1128/aac. 01034-17, 2017 | 84 | 2017 |
| Gender‐related differences in xenobiotic metabolism PL Bonate The Journal of Clinical Pharmacology 31 (8), 684-690, 1991 | 84 | 1991 |
| Pharmacokinetics in drug development PL Bonate, DR Howard Springer, 2016 | 82* | 2016 |
| Phase I and pharmacokinetic study of tasidotin hydrochloride (ILX651), a third-generation dolastatin-15 analogue, administered weekly for 3 weeks every 28 days in patients with … AC Mita, LA Hammond, PL Bonate, G Weiss, H McCreery, S Syed, ... Clinical Cancer Research 12 (17), 5207-5215, 2006 | 78 | 2006 |
| Recommended reading in population pharmacokinetic pharmacodynamics PL Bonate The AAPS journal 7, E363-E373, 2005 | 76 | 2005 |
